A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs ELX 02 (Primary)
  • Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
  • Focus Adverse reactions
  • Sponsors Eloxx Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2018 According to an Eloxx Pharmaceuticals media release, the first four cohorts of the MAD study have been completed and the company is now dosing in the fifth and final cohort. The study will be completed in 2018.
    • 19 Mar 2018 According to an Eloxx Pharmaceuticals media release, the company anticipate that the study will be completed in 2018.
    • 21 Feb 2018 Planned number of patients changed from 36 to 45.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top